Chinese pharmaceutical intermediate enterprises "go out"

　　In February 2020, Porton announced that the company had recently received an order confirmation letter for the intermediate of the antiviral drug Remdesivir (Remdesivir) being developed by its core customer Gilead Sciences.

　　In May 2020, Yaben Chemical developed and completed the production technology related to the intermediate of remdesivir, and ribose has begun commercial mass production.

　　In June 2020, Erkang Pharmaceuticals announced that in order to improve the layout of the industrial chain and ensure stable supply, the company's wholly-owned subsidiary Erkang Biostarch plans to use self-raised funds of 180 million yuan to invest in the construction of m-phenylenediamine in Cambodia. Intermediate project.

　　China's pharmaceutical intermediate industry has developed steadily in recent years, and the international investment and cooperation layout has continued to increase.

　　Pharmaceutical intermediates are the most basic and lowest-end substances in the pharmaceutical production chain

　　Pharmaceutical intermediates are chemical raw materials or chemical products that need to be used in the synthesis of raw materials. There are many kinds of pharmaceutical intermediate products, among which, the drugs with a large share in the clinical application market mainly include antibiotic drug intermediates, antipyretic and analgesic pharmaceutical intermediates, cardiovascular drug intermediates, fluorine-containing intermediates, miscellaneous Many categories such as cyclic drug intermediates. The specific pharmaceutical intermediates include imidazole, furan, phenolic intermediates, microcrystalline cellulose, lactose, dextrin, glycols, powdered sugar, inorganic salts, ethanol intermediates, stearates, etc. product.

　　China's pharmaceutical intermediate industry has gradually entered a mature stage of development

　　After the 1980s, China's pharmaceutical intermediate industry started gradually. Since 2000, under the pressure of environmental protection, developed countries in Europe and the United States have transferred the production of intermediates, which are relatively advanced in pharmaceutical production, to developing countries, and some small and medium-sized enterprises have taken advantage of this opportunity to join the pharmaceutical intermediate industry. The Chinese government has increased investment in the pharmaceutical industry, driving the rapid development of China's pharmaceutical industry. Since the production of pharmaceutical intermediates does not require GMP certification, the industry entry threshold is low. Since 2006, industry participants have increased sharply, and the profit of pharmaceutical intermediate production is higher than that of general chemical products. The production process is similar. A large number of small and medium chemical companies have joined the pharmaceutical intermediate body industry.

　　After 2010, China's pharmaceutical intermediate industry entered a period of industry adjustment, and the demand for downstream export trade in the industry declined. After 2012, the new policy of environmental protection was promulgated, and the growth rate of the industry was relatively slow: the environmental protection policy became increasingly strict, some small and medium-sized enterprises were forced to stop production, and the number of industry participants decreased; the investment in environmental protection construction of production enterprises increased, and the production cost for pharmaceutical intermediates decreased. Production capacity drops. However, in the past five years, with the continuous growth of demand in China's drug market, the scale market of pharmaceutical intermediates has begun to gradually expand.